Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Tortugas Neuroscience launches with $106 million financing

Lucid Diligence Brief: Tortugas Neuroscience launches with $106 million…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma

Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A

Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Stipple Bio $100 million Series A

Lucid Diligence Brief: Stipple Bio $100 million Series A Professional audiences…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Syneron Bio completion of $150 million Series B

Lucid Diligence Brief: Syneron Bio completion of $150 million Series B…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: InSilico Medicine and Lilly global partnership

Lucid Diligence Brief: InSilico Medicine and Lilly global partnership…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Pinnacle Medicines $89 million Series B

Lucid Diligence Brief: Pinnacle Medicines $89 million Series B Professional…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal

Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly

Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Kupando adds €10 million to its Series A for Toll-like receptor assets

Lucid Diligence Brief: Kupando adds €10 million to its Series A for Toll-like…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: PRISM BioLab × Receptor.AI collaboration

Lucid Diligence Brief: PRISM BioLab × Receptor.AI collaboration Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal

Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal Professional…


Privacy Preference Center